Gyre Therapeutics
GYRE
35 hedge funds and large institutions have $13.9M invested in Gyre Therapeutics in 2015 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 12 reducing their positions, and 9 closing their positions.
184% more call options, than puts
Call options by funds: $71K | Put options by funds: $25K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
10% less funds holding
Funds holding: 39 → 35 (-4)
39% less capital invested
Capital invested by funds: $22.9M → $13.9M (-$8.96M)
44% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 9
75% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 12
Top Buyers
Top Sellers
GYRE Hedge Fund Activity: Q4 2015 in Review
35 of the 3,811 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q4 2015, worth a combined $13.9M — down 39% from $22.9M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of GYRE and 5 opened new positions — a net loss of 4 holders — while 12 trimmed existing stakes and 3 added.
The largest buyer was UBS Group, opening a new position worth an estimated $1.25M. The largest seller was RTW Investments, exiting entirely with an estimated $1.77M sold.
- 35 institutional investors held Gyre Therapeutics (GYRE) as of Q4 2015, down from 39 in Q3 2015.
- Funds reported $13.9M of Gyre Therapeutics stock for Q4 2015, down 39% quarter-over-quarter.
- 5 funds opened new Gyre Therapeutics positions in Q4 2015 and 9 closed out, a net change of -4 holders.
- The largest Gyre Therapeutics buyer in Q4 2015 was UBS Group, an estimated $1.25M added.
- The largest Gyre Therapeutics seller in Q4 2015 was RTW Investments, an estimated $1.77M sold.
Based on aggregated 13F filings for Q4 2015.